Treatment options for localized prostate cancer

Canadian Family Physician

Volumn 59, Issue 12, 2013, Pages 1269-1274

  Keyes, Mira ^a   Crook, Juanita ^a,b   Morton, Gerard ^c   Vigneault, Eric ^d   Usmani, Nawaid ^e   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE SEED; SILDENAFIL; TADALAFIL; VARDENAFIL;

ACTIVE SURVEILLANCE; AGE; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANADA; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE SURVEILLANCE; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENERAL PRACTITIONER; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; LOW DOSE RATE BRACHYTHERAPY; PATIENT MONITORING; PENIS ERECTION; POSTOPERATIVE CARE; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SEXUAL FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

BRACHYTHERAPY; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; HUMANS; MALE; PHYSICIAN'S ROLE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84890360088     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-9.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8.
3. Woloshin S, Schwartz LM. Numbers needed to decide. J Natl Cancer Inst 2009;101(17):1163-5.
4. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009;27(5):607-12.
5. Grimm P, Billiet I, Bostwick DG, Dicker AP, Frank SJ, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group. BJU Int 2012;109(Suppl 1):22-9.
6. Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156(5):1707-13.
7. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 2000;283(3):354-60.
8. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172(6 Pt 1):2227-31.
9. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55(1):58-61.
10. Mettlin CJ, Murphy GP, Sylvester J, McKee RF, Morrow M, Winchester DP. Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy. Cancer 1997;80(9):1875-81.
11. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306(11):1205-14.
12. Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010;7(4 Pt 2):1687-98.
13. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan MW, Pontes JE, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008;179(6):2212-7.
14. Bianco FJ Jr, Riedel ER, Begg CB, Kattan MW, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol 2005;173(6):2099-103.
15. Alkhateeb SS, Alibhai SM, Finelli A, Fleshner NE, Jewett MA, Zlotta AR, et al. Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression? Urol Ann 2010;2(2):58-62.
16. Lodde M, Harel F, Lacombe L, Fradet Y. Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World J Urol 2008;26(3):225-9.
17. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. World J Urol 2003;170(3):791-4.
18. Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 2008;26(9):1526-31.
19. Gleave ME, Goldenberg SL, Chin JL, Saad F, Klotz J, Jewett M, et al. CUOGP-95 randomized comparative study of 3 vs 8 months of neoadjuvant hormone therapy prior to prostatectomy 7 year PSA relapse free survival rate. Urology 2009;181(Suppl 4):755.
20. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L, et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8(4):1314-22.
21. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al, editors. AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2002.
22. Union for International Cancer Control. TNM classification of malignant tumours. 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
23. Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009;73(4):860-7.
24. Crook J, Borg J, Evans A, Toi A, Saibishkumar EP, Fung S, et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. Int J Radiat Oncol Biol Phys 2011:80(5):1323-9.
25. Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E. Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: the Hôtel-dieu of Quebec experience. Cancer Radiother 2010;14(3):183-8.
26. Martin AG, Roy J, Beaulieu L, Pouliot J, Harel F, Vigneault E. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: a 12-year Canadian experience. Int J Radiat Oncol Biol Phys 2007;67(2):334-41.
27. Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009;73(4):1023-32.
28. Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008;179(1):141-6.
29. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2011;29(4):362-8.
30. Keyes M, Spadinger I, Liu M, Pickles T, Pai H, Hayden A, et al. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: a long-term study in 1006 patients. Brachytherapy 2012;11(3):199-208.
31. Cesaretti JA, Kao J, Stone NN, Stock RG. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up. BJU Int 2007;100(2):362-7.
32. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54(4):1063-8.
33. Gomez-Iturriaga Pina A, Crook J, Borg J, Lockwood G, Fleshner N. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged < or = 55 years with favorable prostate cancer. Urology 2010;75(6):1412-6.
34. Hayden AJ, Keyes M, Moravan V, McKenzie M, Pickles T. Erectile function following I125 permanent prostate brachytherapy: 5 and 8 years results in 1411 men. Radiother Oncol 2010;96(Suppl 2):S3.
35. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066-73.
36. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103-6.
37. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285-90.
38. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67-74.
39. Pickles T, Keyes M, Morris WJ. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys 2010;76(1):43-9.
40. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009:101(6):374-83.
41. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28(1):126-31.
42. BCCA Prostate Brachytherapy Program-treatment policy and brachytherapy eligibility. Vancouver, BC: BC Cancer Agency; 2012. Available from: www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Genitourinary/Prostate/ Brachytherapy.htm. Accessed 2013 Oct 28.
43. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250-61.
44. Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int 2009;82(1):17-23.
45. Feldman-Stewart D, Brundage MD, Van Manen L, Svenson O. Patient-focussed decision-making in early-stage prostate cancer: insights from a cognitively based decision aid. Health Expect 2004;7(2):126-41.
46. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin 2009;59(6):379-90.
47. Feldman-Stewart D, Tong C, Siemens R, Alibhai S, Pickles T, Robinson JT, et al. The impact of explicit values clarification exercises in a patient decision aid emerges after the decision is actually made: evidence from a randomized controlled trial. Med Decis Making 2012;32(4):616-26.
48. Decision aid computer program for early-stage prostate cancer patients. Kingston, ON: Queen's University. www.queensu.ca/cce/resources/patienteducation/ decisionaid.html. Accessed 2012 Aug 14.